Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

Osteoporosis International

Volumn 27, Issue 5, 2016, Pages 1917-1921

  Popp, A W ^a   Zysset, P K ^a   Lippuner, K ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bone antiresorptives; Bone turnover; Denosumab; Microdamage repair; Rebound associated vertebral fractures

Indexed keywords

CALCIUM; DENOSUMAB; EXEMESTANE; HORMONE RECEPTOR; VITAMIN D; AROMATASE INHIBITOR; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BIOMECHANICS; BLOOD CHEMISTRY; BONE DENSITOMETRY; BONE DENSITY; BONE MARROW EDEMA; BONE REMODELING; BONE TURNOVER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CORTICAL BONE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; HUMAN; LABORATORY TEST; LOW BACK PAIN; LUMBAR SPINE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REBOUND; REBOUND ASSOCIATED VERTEBRAL FRACTURE; RISK FACTOR; SPINE FRACTURE; SPINE RADIOGRAPHY; TRABECULAR BONE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG ADMINISTRATION; OSTEOPOROTIC FRACTURES; SPINAL FRACTURES; TREATMENT WITHDRAWAL;

AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; DENOSUMAB; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; SPINAL FRACTURES; WITHHOLDING TREATMENT;

EID: 84951736171     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3458-6     Document Type: Article

References (26)

1. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629
2. Eastell R, Hannon R (2005) Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 95:151–154
3. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
4. Lonning PE, Geisler J, Krag LE et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126–5137
5. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
6. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227–235
7. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222–229
8. Brown JP, Roux C, Torring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–752
9. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol
10. Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433–443
11. Lambers FM, Bouman AR, Rimnac CM, Hernandez CJ (2013) Microdamage caused by fatigue loading in human cancellous bone: relationship to reductions in bone biomechanical performance. PLoS One 8:e83662
12. Rapillard L, Charlebois M, Zysset PK (2006) Compressive fatigue behavior of human vertebral trabecular bone. J Biomech 39:2133–2139
13. Pattin CA, Caler WE, Carter DR (1996) Cyclic mechanical property degradation during fatigue loading of cortical bone. J Biomech 29:69–79
14. Wolfram U, Wilke HJ, Zysset PK (2010) Valid micro finite element models of vertebral trabecular bone can be obtained using tissue properties measured with nanoindentation under wet conditions. J Biomech 43:1731–1737
15. Seref-Ferlengez Z, Basta-Pljakic J, Kennedy OD, Philemon CJ, Schaffler MB (2014) Structural and mechanical repair of diffuse damage in cortical bone in vivo. J Bone Miner Res 29:2537–2544
16. Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH (1997) Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12:6–15
17. McNamara LM, Prendergast PJ (2005) Perforation of cancellous bone trabeculae by damage-stimulated remodelling at resorption pits: a computational analysis. Eur J Morphol 42:99–109
18. Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11:219–227
19. Roux JP, Wegrzyn J, Arlot ME, Guyen O, Delmas PD, Chapurlat R, Bouxsein ML (2010) Contribution of trabecular and cortical components to biomechanical behavior of human vertebrae: an ex vivo study. J Bone Miner Res 25:356–361
20. Rockoff SD, Sweet E, Bleustein J (1969) The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae. Calcif Tissue Res 3(2):163–175
21. Aubry-Rozier A, Gonzalez-Rodriguez E, Stoll D, Lamy O (2015) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Published online: 28 October 2015. Osteoporos Int
22. Geissler JR, Bajaj D, Fritton JC (2015) American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. J Biomech 48:883–894
23. Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate—results from a randomized double-blind placebo-controlled trial. Bone 50:1389–1393
24. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326
25. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155
26. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56